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abstract 
Despite vaccinations being a breakthrough in preventive 
care, parents’ decisions on vaccination programmes may 
be difficult. This study investigated parents’ attitudes and 
knowledge on vaccines and vaccine-preventable illnesses. 
This was done with a view to identify discrepancies between 
the perceived and actual knowledge on vaccination schedules 
as well as to determine the main reasons for missing 
vaccinations. Following a review of the needs and concerns 
of parents, an information resource which best meets those 
needs was compiled.
IntroductIon
Vaccinations are a vital element in preventive healthcare 
programmes since they reduce the associated morbidity and 
mortality of illnesses.1 Vaccinations have brought a decrease 
in the burden of infectious disease and are considered as the 
greatest success of public health in the last century.2 Apart 
from protecting vaccinated individuals, successful vaccination 
programmes benefit society in general as the incidence of 
disease in the unvaccinated population is indirectly reduced.2
In Malta, vaccination against diphtheria, tetanus and polio is 
obligatory for all children and the rubella vaccine is obligatory 
for females. In addition, parents have to decide which other 
vaccines to give to their children. This involves an important but 
challenging decision. Unfortunately, even though the benefits of 
vaccination are undeniable, vaccines are sometimes considered 
as ‘victims of their own success’. The reason for this is that their 
success in preventing certain illnesses has resulted in generations 
of parents who never experienced the vaccine preventable 
illnesses. This gives the perception that vaccination is futile and 
more attention is thus given to the perceived risks of vaccines 
rather than to the diseases they prevent.3 For this reason a need 
was felt to assess the knowledge, perception and attitudes of 
Maltese parents on vaccines and vaccine-preventable illnesses, as 
well as the factors which affect parents’ decisions to this regard. 
methodology
Data was collected by means of a validated questionnaire 
which was compiled by 270 parents in different settings. 
Stratified random sampling was used to identify representative 
settings - community pharmacies, clinics and other places with a 
high parent attendance. 
The questionnaire consisted of three sections. The first 
section consisted of questions on the decision-making process, 
sources of information used by parents and parents’ perception 
of the need for more information. The second section collected 
information on the children’s vaccination status and reasons 
why specific vaccinations were not given while the third section 
looked at parents opinions on vaccinations not offered for free 
by the NHS and on the parents’ willingness to pay for these 
vaccinations. 
results
The questionnaire was compiled by 270 participants. Most 
respondents were between 30 and 45 years of age (71.3%), 12.3% 
of parents were over 45 years while 16.4% were younger than 30 
years. The average age of the parents’ children was 7.7 years.
sources of InformatIon
81.2% of parents stated that they search for information 
when deciding on their childrens’ vaccination programmes. 
The three main sources of information chosen by parents were 
the paediatrician (35.2%), the family doctor (20.9%) and the 
internet (19.8%). Unfortunately the pharmacist is the source of 
information parents refer to the least (3%).
parents’ perceIVed and actual knoWledge  
and famIlIarIty WIth VaccInatIon schedules
When asked to rate how familiar they feel with 
recommended vaccination schedules and vaccine-preventable 
illnesses, almost 90% claimed that they feel very familiar, 
familiar or moderately familiar. Only 10% of the 259 parents 
who answered this question stated that they feel slightly or 
not familiar with the recommended vaccination schedules. 
However, when in another section parents were presented with 
a list of vaccine preventable illnesses and asked to rate their 
knowledge about the illnesses, their perceived susceptibility for 
an unvaccinated individual and the risk of the illness having 
permanent consequences, the questions had a high non- 
response rate as well as well as a big number of parents who 
expressed their lack of knowledge and familiarity.  This may 
suggest that parents feel more familiar than they actually are and 
that they are making less informed decisions than perceived.
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decIsIons not to VaccInate 
Parents were presented with a list of non-obligatory 
vaccinations and asked to mark whether they have either 
have given or plan to give the particular vaccine to their 
children or did not give and do not plan to give it. Parents 
were further asked to select reasons why they chose not to give 
the particular vaccines. From the given options, the option 
that parents did not know that the vaccine exists was by far 
the most selected one.  As shown in Table 1, this reason was 
selected by 145 parents, far more than the second most cited 
reason, i.e. safety and side effects of vaccines.
attItudes toWards VaccInatIons not proVIded for free 
When asked to rank their agreement with the statement  
‘I am willing to consult my trusted healthcare professional and 
pay for the recommended vaccines’, 92% of responding parents 
claimed that they agree or strongly agree with the statement. 
Furthermore, when presented with the statement, ‘I will wait 
until it is free’ only 6% of responding parents answered that 
they agree or strongly agree with the statement. 
deVelopment of tIlqIm.Info 
The findings of the research were used to develop tilqim.
info, a website aimed to provide parents with necessary 
information to support them in making an informed decision. 
The website content was validated by a seven-member 
validation panel including professionals qualified and 
experienced in the subject as well as people who are not in the 
medical field. This ensured that all content is correct, concise 
and also understandable to the target audience. The website 
Table 1. Reasons for not giving a vaccination
Reason for not vaccinating No. of participants
I do not feel my child is at risk of being infected with such a disease 80
The disease is not serious enough so as to justify vaccination 10
I am not aware that this vaccine exists 145
The vaccine is too expensive 15
I am concerned about safety and side-effects of this vaccine 86
I heard the vaccine can have harmful effects 30
I do not believe in vaccines 12
I forgot 5
I want to give my children the least possible number of vaccines 19
I feel that there are too many vaccinations required 16
I feel that vaccines other than those given for free by the government are not necessary 20
includes information on vaccine-preventable illnesses including 
risks and sequelae. It also illustrates the vaccination schedule 
including vaccines offered through the NHS as well as vaccines 
available in the private market. Other sections in the website 
contain information on the project and its findings as well as 
useful contacts. Tilqim.info was launched in July 2015 and has 
been very well received by healthcare professionals and parents 
alike.
dIscussIon
The study found that the lack of awareness of the availability 
of vaccines, and lack of knowledge about preventable illnesses 
are principal reasons for missed vaccinations. However, 
encouragingly, the findings show that parents are interested 
and willing to obtain more information by discussing with their 
trusted healthcare professionals. 
Being one of the most accessible healthcare professionals, 
the pharmacist is in the ideal position to build a relationship of 
trust and support parents in the process of making informed 
decisions. Unfortunately, the study identified the pharmacist as 
the healthcare professional parents refer to the least. This should 
motivate pharmacists to seek ways of increasing their role in this 
sector. Apart from being open to discussion with parents, it is 
recommended that pharmacists participate in initiatives such as 
education campaigns. Furthermore, pharmacists may promote 
robust information resources which are specifically targeted to 
parents with a view to disseminate evidence-based information 
and decrease the number of vaccinations missed simply due to 
lack of awareness. Tilqim.info is the ideal tool to optimise the 
role of pharmacists and healthcare professionals in this field. ref
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